Astellas Pharma has entered an agreement to buy Iveric Bio for about US$5.9 billion.
It is the biggest acquisition for the Japanese-based company, and gives it access to a range of ophthalmology treatments, including avacincaptad pegol (ACP), a promising drug under development for geographic atrophy secondary to age-related macular degeneration.
